Appendix 1: Publicly Funded Quadrivalent Influenza Vaccines 2017-18

	FluLaval® Tetra (GSK) QIV split virion	**Fluzone® Quadrivalent** (SP) QIV split virion
Population	Everyone ≥ 6 months	Everyone ≥ 6 months
Dose	0.5 mL IM	0.5 mL IM
Components	Latex and antibiotic free and contains both influenza A strains and B viral strains, sodium chloride, potassium chloride, disodium hydrogen phosphate heptahydrate, potassium dihydrogen phosphate, α-tocopheryl hydrogen succinate, and polysorbate 80, and may contain traces of egg proteins (ovalbumin), sodium deoxycholate, ethanol, formaldehyde and sucrose. Thimerosal added as a preservative to multidose vials.	Latex, antibiotic and gelatin free and contains all surface antigens of this year's influenza A and B viral strains, formaldehyde, sodium phosphate-buffered, isotonic sodium chloride solution, and Triton® X-100, and may contain traces of egg protein and sucrose. Thimerosal is added as a preservative only to multidose vials.
Normal and Expected Reactions These reactions are mild to moderate and generally last 1-4 days.	• Soreness, warmth, redness, and swelling at the injection site. • Temporary limited movement of the immunized arm or leg. • Headache, fever, tiredness, muscle aches, and chills. • Loss of appetite.	• The most common reactions occurring after vaccine administration are injection site pain (11%-57%), erythema (7%-30%) and edema (6%-21%). • The most common systemic reactions observed after vaccine administration are asthenia (2%-18%), headache (2%-10%) and myalgia (2%-9%).
Presentation	• 5 mL multidose vial containing 10 doses of 0.5 mL	• 5 mL multidose vial containing 10 doses of 0.5 mL • 0.5 mL prefilled syringes (thimerosal free) - Public Health only
Contra-indications	• Persons with a history of a severe allergic or anaphylactic reaction to a previous influenza vaccine dose or any component of the influenza vaccine should discuss their situation with a public health nurse or their physician. • Persons who developed GBS within six weeks of a previous influenza vaccine.	• Persons with a history of a severe allergic or anaphylactic reaction to a previous influenza vaccine dose or any component of the influenza vaccine should discuss their situation with a public health nurse or their physician. • Persons who developed GBS within six weeks of a previous influenza vaccine.
Instructions for Administration	• Do not administer vaccine from a vial that has been opened for ≥28 days or has expired. • To get 10 doses out of a vials, GSK recommends that each 0.5 mL dose is withdrawn into a 1 mL syringe equipped with a needle gauge not larger than 23-G.	• Vaccine may be administered from a MDV that has been opened up to the expiry date indicated on the vial.
Special Instructions –	• Gently shake the vial before administration. • Date vials when opened. • Store 2°C-8°C. • Do not freeze or use if vaccine has been frozen. • Protect from light. • Pre-drawing is not recommended. • The Ministry recommends that vaccines be administered directly from the fridge or cooler and not warmed to room temperature prior to administration.	